AMRUTANJAN vs KREBSBIO: Stock Comparison

Amrutanjan Health Care Limited vs Krebs Biochemicals and Industries Limited

Live data: 22 July 2026, 3:07 PM IST • Source: NSE and company filings

Amrutanjan Health Care Limited is the larger company by market capitalisation. Amrutanjan Health Care Limited shows a higher dividend yield, a higher ROCE and a higher net margin, while Krebs Biochemicals and Industries Limited shows a lower P/E and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Amrutanjan Health Care Limited and Krebs Biochemicals and Industries Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, AMRUTANJAN is more favourable on 6 of 9 scored metrics and KREBSBIO on 3These counts are context-free and are not an overall rating.

Key Differences

Market Cap
AMRUTANJAN is the larger company
₹1,528 Cr vs ₹117 Cr
P/E Ratio
KREBSBIO has a lower P/E
0x vs 26.9x
P/B Ratio
KREBSBIO has a lower P/B
0x vs 4.21x
EPS
AMRUTANJAN has higher earnings per share
₹20.01 vs ₹-7.85
Dividend Yield
AMRUTANJAN has a higher dividend yield
1.02% vs 0%
Revenue Growth (TTM YoY)
KREBSBIO has faster revenue growth
11.6% vs 10.5%
EPS Growth (TTM YoY)
AMRUTANJAN has faster EPS growth
6.7% vs 0%
ROCE
AMRUTANJAN has a higher ROCE
31.4% vs -15.4%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricAMRUTANJANKREBSBIO
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricAMRUTANJANKREBSBIO
Live Price₹529.6₹53.41
Day Change-1.67%-3.03%
Volume21,8921,997
52-Week High₹790.95₹82.49
52-Week Low₹486₹38.33
Distance from 52W High-33.04%-35.25%

Valuation

MetricAMRUTANJANKREBSBIO
Market Cap₹1,528 Cr₹117 Cr
P/E Ratio26.9x0x
P/B Ratio4.21x0x
EPS₹20.01₹-7.85
Book Value₹128.04₹-75.5
Dividend Yield1.02%0%

Growth

MetricAMRUTANJANKREBSBIO
Revenue Growth (TTM YoY)10.5%11.6%
EPS Growth (TTM YoY)6.7%0%
Qtr Sales Growth11.6%
Qtr Profit Growth71.7%

Profitability & Leverage

MetricAMRUTANJANKREBSBIO
ROE20%
ROCE31.4%-15.4%
Net Margin11.52%-71.35%
Operating Margin17.7%-23%
Debt to Equity0.02x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricAMRUTANJANKREBSBIO
Promoter Holding46.52%72.74%
FII Holding2.44% 0.27 pp0.5%
DII Holding12.28% 0.38 pp0%
Public Holding38.72% 0.11 pp26.76%

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Amrutanjan Health Care Limited and Krebs Biochemicals and Industries Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.